scholarly journals Voice changes associated with inhaled steroids 1n obstructive lung disease patients

2020 ◽  
Vol 12 (1) ◽  
pp. 1-7
Author(s):  
Baraka M ◽  
Hossam ElDessouky ◽  
Ahmed Amer Khamees ◽  
Ayman Ali Abd ElFattah ◽  
Eman Ezzat ◽  
...  
Keyword(s):  
Side Effects ◽  
Lung Disease ◽  
Bronchial Asthma ◽  
Obstructive Lung Disease ◽  
Inhaled Corticosteroids ◽  
Group I ◽  
Voice Changes ◽  
Significant Difference ◽  
Local Side ◽  
Laryngeal Examination

Background/Aims: The widespread use of inhaled corticosteroids (ICS) for the treatment of obstructive lung disease may be associated with both systemic and local side effects. These local side effects; including voice problems, oropharyngeal candidiasis, throat clearing, sense of fullness, pharyngitis, and cough, are generally viewed as minor complications of therapy in what is called steroid inhaler laryngitis (SIL). Few studies have been performed to specifically evaluate local side effects of ICS. However, they can be clinically significant, affect patient's quality of life, hinder compliance with therapy, and mask symptoms of more serious disease. The aim of this study is to examine the effect of ICS on the larynx and subsequent voice changes, and highlighting if these voice problems related to the type of inhaled corticosteroids in order to determine the importance of regular laryngeal examination in those patients. Methods: 40patients with bronchial asthma and 40 patients with COPD admitted to Chest department in Menoufia and Zagazig University Hospitals during the period from March 2017 to March 2019 were included in the study. They were divided according to the type of cortisone used into four groups; group (I): beclomethasone dipropionate (BDP) users, group (II): budesonide (BUD) users, group (III): Ciclesonide users and group (IV): fluticasone propionate (FP) users. They were evaluated as regards videolaryngoscopic examination and acoustic analysis Results: The age of the patients with bronchial asthma ranged from 29 to 42years and the age of the patients with COPD ranged from 31 to 43years. There was a statistically significant difference among the four groups of cortisone inhalation regarding laryngoscopic findings; as presence of congestion (diffuse and local), mucus spills on VF and glottis gap were all higher in frequency among the group of patients used fluticasone FP, while least signs found among ciclesonide users. Also, average pitch, Jitter, H/N ratio and MPT were more worsen in fluticasone group when compared with Ciclesonide group. Conclusion: obstructive lung disease patients may suffer from voice problems related to the type of inhaled corticosteroids that could be fade when therapy is stopped. So, regular laryngeal examination in those patients is important.

scholarly journals Severe Oro-laryngeal Thrush Following Excessive Use of Steroid Inhaler

2020 ◽  
Vol 9 (1) ◽  
Author(s):  
Marina MB ◽  
Ramli R ◽  
Primuharsa Putra SHA
Keyword(s):  
Side Effects ◽  
Muscle Power ◽  
Inhaled Corticosteroids ◽  
Fungal Infections ◽  
Complete Recovery ◽  
Asthmatic Patients ◽  
Inhaled Steroids ◽  
Laryngeal Mucosa ◽  
Loss Of Appetite ◽  
Local Side

Introduction: Inhaled steroids such as fluticasone propionate and beclomethasone dipropionate play an important role in the treatment of bronchial asthma. Its usage facilitates disease control in asthmatic patients, resulting in improved quality of life. Because of its benefit, the inhaled steroid is used extensively, at higher doses and for longer duration. However, the localized effects of inhaled corticosteroids on oral/laryngeal mucosa, such as fungal infections can be problematic. Case Report: We report a case of oropharyngeal and laryngeal candidiasis following a long period and high doses of inhaled steroid in a 42-year-old male. He presented with a complaint of increasing tiredness, phlegm, intermittent wheezing and hoarseness for 2-3 months. There was no weight loss or loss of appetite. He has been using inhaled steroids and long acting bronchodilators in increasing doses for his claimed ‘wheezing’ despite the negative history of asthma. The inhaled steroids were fluticasone dipropionate at doses of 500-100 mcg daily for 2-3 months. Results: Examination revealed widespread oral thrush involving the oral cavity, oropharynx and larynx. There was no cushingoid habitus. His muscle power was of 5/5 bilaterally and his lungs were clear. Lung function and chest film were also normal. The steroid was stopped immediately and flucanozole and nystatin syrup were prescribed. The patient made an uneventful and complete recovery. Conclusion: We conclude that patients on inhaled corticosteroids should be monitored for local side effects. Physicians should be aware not only of the systemic but also of the local side effects of inhaled corticosteroids. Patients may increase doses without the knowledge of their physicians and subsequently suffer the adverse effects either local or systemic.

scholarly journals Risk of pneumonia in obstructive lung disease: A real-life study comparing extra-fine and fine-particle inhaled corticosteroids

PLoS ONE ◽  
2017 ◽  
Vol 12 (6) ◽  
pp. e0178112 ◽  
Author(s):  
Samatha Sonnappa ◽  
Richard Martin ◽  
Elliot Israel ◽  
Dirkje Postma ◽  
Wim van Aalderen ◽  
...  
Keyword(s):  
Lung Disease ◽  
Fine Particle ◽  
Obstructive Lung Disease ◽  
Inhaled Corticosteroids ◽  
Real Life ◽  
Life Study ◽  
Real Life Study

The Local Side Effects of Inhaled Corticosteroids

CHEST Journal ◽  
2004 ◽  
Vol 126 (1) ◽  
pp. 213-219 ◽  
Author(s):  
Nicholas J. Roland ◽  
Rajiv K. Bhalla ◽  
John Earis
Keyword(s):  
Side Effects ◽  
Inhaled Corticosteroids ◽  
Local Side

scholarly journals Prevalence of Respiratory Symptoms, Bronchial Asthma and Obstructive Lung Disease among Tannery Workers

2018 ◽  
Vol 2 (1) ◽  
pp. 033-042
Author(s):  
Jamall Asad ◽  
Mehmood Atif ◽  
Khatoon Fehmida ◽  
Putus Tuula ◽  
Savolainen Heikki ◽  
...  
Keyword(s):  
Lung Disease ◽  
Bronchial Asthma ◽  
Obstructive Lung Disease ◽  
Respiratory Symptoms ◽  
Tannery Workers

scholarly journals Effect of Halita mouthwash on oral halitosis treatment: A randomized triple-blind clinical trial

2019 ◽  
Vol 13 (1) ◽  
pp. 31-35
Author(s):  
Zahra Jamali ◽  
Mahdieh Alipour ◽  
Syamand Ebrahimi ◽  
Marzie Aghazadeh
Keyword(s):  
Clinical Trial ◽  
Statistical Analysis ◽  
Side Effects ◽  
Oral Cavity ◽  
Oral Malodor ◽  
Group I ◽  
Significant Difference ◽  
The World ◽  
Chi Squared ◽  
Organoleptic Score

Background. Halitosis (oral malodor) is a common problem all over the world and its prevalence has been estimated at 23‒ 50%. Halitosis originates from oral cavity in 85% of patients. This clinical trial was conducted to evaluate the efficacy of the Halita mouthwash in oral halitosis treatment. Methods. Fifty subjects with an organoleptic score of >2 at baseline participated in this triple-blinded clinical trial. Subjects were divided into 2 groups. Group I subjects (N=25) were instructed to rinse with 0.2% chlorhexidine (CHX) mouthwash twice a day for 1 week. Group II subjects (N=25) used Halita mouthwash with the same instruction. Halitosis was evaluated at baseline and one week after using the mouthwashes by organoleptic method. Data were analyzed with chi-squared and Mann-Whitney U tests (P<0.05). Results. In the Halita group subjects exhibited 2.04±0.65 reduction in OLS. OLS reduction in the chlorhexidine group was 1.95±0.74. Statistical analysis showed no significant difference between the two groups (P>0.05). Conclusion. Based on the results, Halita mouthwash has the same effect on oral halitosis as routine 0.2% CHX mouthwash. Halita mouthwash has fewer side effects because of lower concentration of chlorhexidine. Therefore 0.2% CHX mouthwash could be replaced by Halita mouthwash for the treatment of halitosis.

scholarly journals Inhaled Corticosteroids and the Lung Microbiome in COPD

Biomedicines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1312
Author(s):  
Holly R. Keir ◽  
Marco Contoli ◽  
James D. Chalmers
Keyword(s):  
Lung Disease ◽  
Obstructive Lung Disease ◽  
Inhaled Corticosteroids ◽  
Bacterial Load ◽  
Chronic Obstructive Lung Disease ◽  
Lower Airway ◽  
Chronic Obstructive ◽  
Pharmacological Management ◽  
Lung Microbiome ◽  
Increased Risk

The Global Initiative for Chronic Obstructive Lung Disease 2021 Report recommends inhaled corticosteroid (ICS)-containing regimens as part of pharmacological treatment in patients with chronic obstructive lung disease (COPD) and frequent exacerbations, particularly with eosinophilic inflammation. However, real-world studies reveal overprescription of ICS in COPD, irrespective of disease presentation and inflammatory endotype, leading to increased risk of side effects, mainly respiratory infections. The optimal use of ICS in COPD therefore remains an area of intensive research, and additional biomarkers of benefit and risk are needed. Although the interplay between inflammation and infection in COPD is widely acknowledged, the role of the microbiome in shaping lower airway inflammation has only recently been explored. Next-generation sequencing has revealed that COPD disease progression and exacerbation frequency are associated with changes in the composition of the lung microbiome, and that the immunosuppressive effects of ICS can contribute to potentially deleterious airway microbiota changes by increasing bacterial load and the abundance of potentially pathogenic taxa such as Streptococcus and Haemophilus. Here, we explore the relationship between microbiome, inflammation, ICS use and disease phenotype. This relationship may inform the benefit:risk assessment of ICS use in patients with COPD and lead to more personalised pharmacological management.

scholarly journals Real-world efficacy of the impulse oscillometry system for the management of bronchial asthma

2020 ◽  
Author(s):  
Hiroyuki Sugawara ◽  
Atsushi Saito ◽  
Saori Yokoyama ◽  
Kazunori Tsunematsu ◽  
Hirofumi Chiba ◽  
...  
Keyword(s):  
Particle Size ◽  
Bronchial Asthma ◽  
Inhaled Corticosteroids ◽  
Strong Association ◽  
Therapeutic Effects ◽  
Impulse Oscillometry ◽  
Asthma Control Test ◽  
Subtype Classification ◽  
Predominant Type ◽  
Significant Difference

Abstract Background: Bronchial asthma (BA) has different phenotypes, and it requires a clinically effective subtype classification system. The impulse oscillometry system (IOS) is a novel device used in respiratory functional tests. However, its efficacy has not been validated. Therefore, this study aimed to assess the relationship between BA and the IOS parameters, and the difference in the therapeutic effects of inhaled corticosteroids (ICSs) among the subtype classifications was evaluated using the IOS.Methods: The following ICSs were randomly prescribed in daily medical care: coarse-particle ICS (fluticasone propionate [FP]), fine-particle ICS (mometasone furoate [MF]), and moderate-particle ICS (budesonide [BUD]). The treatment effects were assessed using the Asthma Health Questionnaire (AHQ) and the Asthma Control Test (ACT), and were compared among the three subtypes (central predominant, peripheral predominant, and resistless) using the IOS.Results: In the central predominant type, the AHQ score of the MF group was significantly higher than that of the FP and BUD groups. In the peripheral predominant type, the MF group had a significantly lower AHQ than the FP group. In the resistless type, no significant difference was observed in the AHQ scores among the three groups. Moreover, similar results were obtained in the study using ACTConclusions: A strong association was observed between IOS subtype classification and ICS particle size in terms of therapeutic efficiency in BA. This result indicates that the ICS particle size must be identified using the IOS subtype classification before treatment.

scholarly journals THE EFFECT OF MAGNETO-LASER THERAPY ON THE PHENOTYPE OF BASOPHILS IN CHILDREN WITH ATOPIC ASTHMA

2019 ◽  
Vol 29 (2) ◽  
pp. 35-38
Author(s):  
Elena Asiryn ◽  
Pavel Novikov ◽  
Volha Matsiushchanka ◽  
Nadiezhda Titova ◽  
Lukas Vaidelys ◽  
...  
Keyword(s):  
Laser Therapy ◽  
Bronchial Asthma ◽  
Inhaled Corticosteroids ◽  
Atopic Asthma ◽  
Relative Level ◽  
Atopic Bronchial Asthma ◽  
Significant Difference ◽  
Group A ◽  
The Absolute ◽  
Group B

In recent years there has been growing evidence to suggest a major role of basophils alongside eosinophils and mast cells in allergic inflammation. The aim of this study was to analyze the dynamics of the basophil phenotypes after the use of magneto-la-ser therapy in children with atopic bronchial asthma. Materials and methods. A total of 66 children with mild persistent atopic bronchial asthma (aged 6 to 18 years old) were examined. Group A included 34 children who received magneto-laser therapy together with basic asthma treatment (low dose of inhaled corticosteroids). Group B included 32 children who received only basic asthma therapy. The level of CD203с + , CD203с + CD63 + , CD203с + IgE + basophils was determined in peripheral blood in the beginning of the study, after 2 weeks and after 3 months. Results. A statistically significant decrease in the absolute levels of CD203с+CD63+ and CD203с + IgE + basophils and in the relative level of CD203с + IgE + among all CD203с + basophils was determined in group A after magneto-laser therapy. The comparison of group A and group B indices revealed a significant difference between the relative level of CD203с + IgE + basophils after 12-15 days from the beginning of the study. This indicator was significantly lower in group A than in group B (p&lt;0.05). The absolute level of CD203с + IgE + basophils was significantly lower in group A in comparison with group B after 82-90 days (p&lt;0.05). Conclusions. Magneto-laser therapy can change the phenotype of basophils in children with atopic bronchial asthma, causing suppression of proallergic pa-rameters. Considering these results there is reason to believe, that it is possible to use this method as an additional immunocorrective treatment in patients with basophilic phenotype of atopic asthma.

Physiology and Morphology of Bronchiolitis

PEDIATRICS ◽  
1964 ◽  
Vol 33 (5) ◽  
pp. 792-792
Author(s):  
J. J. ROBBINS
Keyword(s):  
Lung Disease ◽  
Bronchial Asthma ◽  
Obstructive Lung Disease ◽  
Flow Volume ◽  
Outflow Resistance ◽  
Pressure Flow ◽  
Expiratory Phase ◽  
Infancy And Childhood

I was very much interested in Dr. Ingeborg Krieger's excellent study of pressure-flow-volume relationships in acute infantile bronchiolitis, published in Pediatrics, 33:45, 1964. I am wondering if Dr. Krieger is acquainted with the recently published studies by Engel of the anatomy of the bronchiolar tree in infancy and childhood which might well provide an explanation for the seemingly paradoxical lack of rise in outflow resistance and prolongation of expiratory phase as is characteristic of other obstructive lung disease as bronchial asthma.

Sign in / Sign up

Export Citation Format

Share Document